Related Experiment Videos
Antitumor activity of tilorone hydrochloride on a transplantable rat adenocarcinoma
Abstract:
Tilorone HCL, administered in drinking water, retarded and slowed significantly the growth of the transplantable R3230 AC rat adenocarcinoma in Fischer 344 rats. This effect is dose-related; from the average three dosage levels studied, daily intake of 30 mg/kg rat/day was found to be optimal. However, Stadie slices of tumors from Tilorone-treated animals when transplanted, took, and showed a growth curve similar to tumors from untreated rats. Exposure to Tilorone does not select tumor cell clones of lesser malignancy or different histopathology.
Insights
Tilorone HCL significantly slowed R3230 AC rat adenocarcinoma growth in a dose-dependent manner. However, tumor cells from treated rats showed similar growth, indicating Tilorone HCL does not alter malignancy.
Area of Science:
- Oncology
- Pharmacology
Background:
- The R3230 AC adenocarcinoma is a transplantable tumor model in Fischer 344 rats.
- Tilorone HCL is an investigational drug with potential anti-cancer properties.
Purpose of the Study:
- To evaluate the efficacy of Tilorone HCL in inhibiting the growth of R3230 AC rat adenocarcinoma.
- To determine the dose-response relationship and assess the impact of Tilorone HCL on tumor cell malignancy.
Main Methods:
- Administration of Tilorone HCL in drinking water to Fischer 344 rats bearing R3230 AC tumors.
- Dose-ranging study to identify optimal Tilorone HCL dosage.
- Transplantation of tumor slices from Tilorone HCL-treated and untreated rats to assess tumor take and growth kinetics.
Main Results:
- Tilorone HCL significantly retarded and slowed tumor growth in a dose-dependent manner.
- An optimal daily intake of 30 mg/kg rat/day was identified.
- Tumor slices from Tilorone HCL-treated rats exhibited similar growth curves to those from untreated rats post-transplantation.
Conclusions:
- Tilorone HCL demonstrates significant anti-proliferative effects on R3230 AC rat adenocarcinoma.
- The observed tumor growth inhibition is likely a direct effect of Tilorone HCL on tumor cells during exposure, rather than a selection for less malignant clones.
- Further research is warranted to understand the precise mechanisms of Tilorone HCL's action and its clinical applicability.